The FTC approved Bristol-Myers’ $74 billion takeover of Celgene last November, making it one of the largest deals in pharmaceutical history.
The changes to the logo include switching from blue to purple, incorporating a stylized hand and a new font. The company also decided to drop the hyphen in “Bristol-Myers.”
Kathryn Metcalfe, executive vice president of corporate affairs at Bristol Myers, told Medical, Marketing and Media that the rebrand is meant to unify the Bristol Myers and Celgene brands and to reintroduce the company to the market after the acquisition.
“We needed something that was fresh, more representative of who we are and who we will be in the future,” she said.
The Celgene brand will be phased out, an unusual move in the pharma world, as many companies keep the acquired company’s name as part of the brand, according to Medical, Marketing and Media.
Read the full article here.
More articles on pharmacy:
Mount Carmel to pay $477K after pharmacists cited in fatal patient overdoses
Express Scripts, 6 others receive PBM excellence awards
Public Citizen slams the FDA for not identifying drug in coronavirus-related shortage
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.